RedHill Biopharma Prices Concurrent Public Offering and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
RedHill Biopharma Prices Concurrent Public Offering and Registered Direct Offering of its American Depositary Shares and Warrants 

TEL-AVIV, Israel, Dec. 21, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ: RDHL ) (TASE: RDHL ) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced the pricing of its previously announced underwritten public offering and its concurrent registered direct offering of American Depositary Shares (“ADSs”) and warrants to purchase ADSs for expected aggregate gross proceeds, before deducting underwriting agent discounts and commissions, placement agent fees and other offering expenses, of approximately $38 million.

The pricing for the underwritten public offering was for a total number of 2,250,000 ADSs, each representing ten of its ordinary shares, and warrants to purchase 1,125,000 ADSs, for expected gross proceeds of approximately $23 million. The pricing for the concurrent registered direct offering was for a total number of 1,463,415 ADSs and warrants to purchase 731,708 ADSs for expected gross proceeds of approximately $15 million.

The price in both offerings is $10.25 for a fixed combination of one ADS and a warrant to purchase 0.5 of an ADS. The warrants in both offerings will have a per ADS exercise price of $13.33, and have a term of three years.

The offering is expected to close on December 27, 2016, subject to customary closing conditions. RedHill has also granted the underwriters in the underwritten public offering a 30-day option to purchase up to 337,500 additional ADSs, and warrants to purchase up to 168,750 additional ADSs, or any combination thereof.

Roth Capital Partners is acting as sole book-running manager and Echelon Wealth Partners is acting as Canadian manager for the underwritten public offering with respect to sales in Canada. Roth Capital Partners is acting as placement agent in the registered direct offering.

The Company intends to use the proceeds from both offerings to fund clinical development programs, for potential acquisitions, to support commercial operations and for general corporate purposes.

The ADSs and warrants will be issued pursuant to a shelf registration statement that was previously filed with, and declared effective by, the Securities and Exchange Commission (the “SEC”). A preliminary prospectus supplement related to the underwritten public offering has been filed with the SEC and is available on the SEC's website located at www.sec.gov , and a final prospectus supplement related to each of the offerings will be filed with the SEC and will be available on the SEC’s website.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

This offering will be made only by means of a prospectus. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the underwritten public offering may be obtained, when available, by contacting Roth Capital Partners, Attention: Equity Capital Markets, 888 San Clemente Drive, Newport Beach, CA 92660, or by telephone at 800-678-9147, or by email at RothECM@roth.com .

About RedHill Biopharma Ltd.: RedHill Biopharma Ltd. (NASDAQ: RDHL ) (TASE: RDHL ) is a biopharmaceutical company headquartered in Israel, primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. RedHill’s pipeline of proprietary products includes: (i) RHB-105 - an oral combination therapy for the treatment of Helicobacter pylori infection with successful results from a first Phase III study; (ii) RHB-104 - an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study and a completed proof-of-concept Phase IIa study for multiple sclerosis; (iii) BEKINDA ® (RHB-102) - a once-daily oral pill formulation of ondansetron with an ongoing Phase III study for acute gastroenteritis and gastritis and an ongoing Phase II study for IBS-D; (iv) RHB-106 - an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; (v) YELIVA ® (ABC294640) - a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory and gastrointestinal indications; (vi) MESUPRON - a Phase II-stage first-in-class, orally-administered uPA inhibitor, targeting gastrointestinal and other solid tumors and (vii) RIZAPORT ® (RHB-103) - an oral thin film formulation of rizatriptan for acute migraines, with a U.S. NDA currently under discussion with the FDA and marketing authorization received in Germany in October 2015.

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company’s research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate development efforts; (ii) the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; (iii) the extent and number of additional studies that the Company may be required to conduct and the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company’s therapeutic candidates; (v) the Company’s ability to establish and maintain corporate collaborations; (vi) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (vii) the interpretation of the properties and characteristics of the Company’s therapeutic candidates and of the results obtained with its therapeutic candidates in research, preclinical studies or clinical trials; (viii) the implementation of the Company’s business model, strategic plans for its business and therapeutic candidates; (ix) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (x) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xi) estimates of the Company’s expenses, future revenues capital requirements and the Company’s needs for additional financing; (xii) competitive companies and technologies within the Company’s industry; and (xiii) the impact of the political and security situation in Israel on the Company's business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC on February 25, 2016. All forward-looking statements included in this Press Release are made only as of the date of this Press Release. We assume no obligation to update any written or oral forward-looking statement unless required by law.

Company contact: Adi Frish Senior VP Business Development & Licensing RedHill Biopharma +972-54-6543-112 adi@redhillbio.com IR contact (U.S.): Marcy Nanus Senior Vice President The Trout Group +1-646-378-2927 Mnanus@troutgroup.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Memorial Manor's Five-Star Signal in Long-Term Care

Updated Category News Views 106

Care quality is the only score that matters here A nursing home recognition is not the sort of news anybody should read like a trophy-case press release and then forget by lunch. Families make decisions around long-term care when they are tired, worried, and often dealing with a parent or spouse whose needs have changed fast. In that setting, a facility putting up both a...

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 154

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading
Avelo Tests Loyalty Math With WeSalute Fare Discounts

Updated Category News Views 81

Airline discounts can look like generosity until the load factor starts talking back. Avelo Airlines has joined WeSalute with fare discounts for active-duty military members, veterans, first responders, nurses, medical professionals, public servants, teachers and eligible family members. It is a sensible move for a young carrier built around smaller airports and lower...

Continue Reading
AES Clears FERC, Nearing Its December 2 Takeover Close

Updated Category News Views 10

One more regulatory gate just swung open for AES, and this deal is finally staring at the finish line instead of wandering through the usual approval swamp. The Federal Energy Regulatory Commission has issued its final order approving AES's acquisition by a consortium led by Global Infrastructure Partners, part of BlackRock, and EQT Infrastructure VI. The last major...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 117

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 97

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
Abacus Global Faces Scrutiny Over Accounting Practices

Updated Category News Views 0

Storm Clouds Gather over Abacus Global Management If it ain't one thing, it's another—at least that's what folks holding the bag with Abacus Global (ABX) are thinking right now. News of a pending investigation has dropped like a lead balloon, and the air is thick with scrutiny over their financial dealings. We're jawing about related-party transactions now under the...

Continue Reading
Labcorp's Brazil Trial Push Has Promise and Plenty to Prove

Updated Category News Views 24

Brazilian clinical-trial kit deliveries may soon spend less time tangled in international shipping. That is the practical heart of Labcorp's newly announced collaboration with Grupo Fleury, and frankly, practical is plenty good in this business. Labcorp plans to begin assembling clinical-trial kits locally in Brazil in early 2027, then add laboratory operations by the end...

Continue Reading
A Faded Sign Is a Quiet Leak in Storefront Demand Today

Updated Category News Views 31

Sunlight does not care what the marketing budget said. A storefront can have a decent product, a clean interior and a capable crew, then lose the first impression before anyone reaches the door because its sign looks tired. That is the plainspoken point behind FASTSIGNS' latest guidance on outdoor sign lifespan. This is not glamorous stuff, but it is operationally...

Continue Reading
Unishippers Climbs 18 Slots on 32.4% Sales Growth Run

Updated Category News Views 50

Thirty new franchise units can move the needle fast Unishippers did not inch its way up the Franchise Times Top 400; it put up a number that deserves a hard look. Sales rose 32.4% in 2025, the company added 30 franchise units, and the result was an 18-place jump to No. 81 on the 2026 ranking. In the shipping category, it was named the sales-growth leader. For a business...

Continue Reading

Top 5 Most Recently Viewed Articles

The Exclusion of XRP from Trump's Crypto Reserve Explained

Updated Category News Views 679

Understanding the Strategic Crypto Reserve Exclusion The cryptocurrency world was recently shaken when President Donald Trump issued an executive order that left notable omissions. Among these was XRP, a digital asset that Ripple and its supporters had hoped to see included in a U.S. sovereign crypto reserve. The Ripple Effects of Trump's Order After investing heavily in...

Continue Reading
UKG Stands Out as a Top Leader in Workforce Management Solutions

Updated Category News Views 168

UKG Secures Top Spot in Workforce Management UKG, a leading provider in HR, payroll, workforce management, and cultural solutions, has recently earned recognition for its exceptional contributions to the workforce management field. The company has been named a Leader in the NelsonHall New World Workforce Management 2024 evaluation, showcasing its strong performance across...

Continue Reading
Zillow Unveils Innovative AI Virtual Staging for Listings

Updated Category News Views 283

Zillow Introduces AI-Powered Virtual Staging In an exciting development for real estate, Zillow has recently launched an innovative feature known as Virtual Staging. This tool harnesses the power of artificial intelligence to enhance how listings are showcased, making the home-buying experience even more engaging for potential buyers. Creating a Visual Experience for Home...

Continue Reading
Balchem Corporation: Innovating Health and Nutrition Solutions

Updated Category News Views 296

Balchem Corporation's Upcoming Conference Presentation Balchem Corporation, a prominent global manufacturer known for its specialty ingredients aimed at health and nutrition markets, is set to make a significant presentation at an upcoming virtual conference. The CJS Securities New Ideas for the New Year Virtual Conference will feature notable company figures, including...

Continue Reading
Projected Growth of Cottonseed Oilseed Processing Market

Updated Category News Views 85

Overview of Cottonseed Oilseed Processing Market Growth The cottonseed oilseed processing market is experiencing significant growth, projected to reach $7.7 billion within a decade, showcasing a compound annual growth rate (CAGR) of 6.8%. The increasing demand for vegetable oils, primarily for their versatility and cost-effectiveness, plays a crucial role in this market's...

Continue Reading